Incyte Corp (INCY)
53.03
-0.50
(-0.93%)
USD |
NASDAQ |
May 10, 13:46
Incyte Enterprise Value: 8.169B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 8.169B |
| May 08, 2024 | 8.164B |
| May 07, 2024 | 8.358B |
| May 06, 2024 | 8.292B |
| May 03, 2024 | 8.221B |
| May 02, 2024 | 8.070B |
| May 01, 2024 | 8.037B |
| April 30, 2024 | 7.837B |
| April 29, 2024 | 7.951B |
| April 26, 2024 | 7.754B |
| April 25, 2024 | 7.641B |
| April 24, 2024 | 7.767B |
| April 23, 2024 | 7.747B |
| April 22, 2024 | 7.807B |
| April 19, 2024 | 7.904B |
| April 18, 2024 | 8.010B |
| April 17, 2024 | 7.987B |
| April 16, 2024 | 8.099B |
| April 15, 2024 | 8.147B |
| April 12, 2024 | 8.240B |
| April 11, 2024 | 8.481B |
| April 10, 2024 | 8.499B |
| April 09, 2024 | 8.566B |
| April 08, 2024 | 8.510B |
| April 05, 2024 | 8.553B |
| Date | Value |
|---|---|
| April 04, 2024 | 8.496B |
| April 03, 2024 | 8.568B |
| April 02, 2024 | 8.685B |
| April 01, 2024 | 8.867B |
| March 31, 2024 | 8.941B |
| March 28, 2024 | 9.135B |
| March 27, 2024 | 9.169B |
| March 26, 2024 | 9.041B |
| March 25, 2024 | 9.250B |
| March 22, 2024 | 9.137B |
| March 21, 2024 | 9.304B |
| March 20, 2024 | 9.420B |
| March 19, 2024 | 9.441B |
| March 18, 2024 | 9.218B |
| March 15, 2024 | 9.450B |
| March 14, 2024 | 9.488B |
| March 13, 2024 | 9.573B |
| March 12, 2024 | 9.665B |
| March 11, 2024 | 9.993B |
| March 08, 2024 | 9.820B |
| March 07, 2024 | 9.598B |
| March 06, 2024 | 9.649B |
| March 05, 2024 | 9.569B |
| March 04, 2024 | 9.753B |
| March 01, 2024 | 9.602B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
7.641B
Minimum
Apr 25 2024
22.39B
Maximum
Jun 22 2020
14.36B
Average
14.49B
Median
Enterprise Value Benchmarks
| Biogen Inc | 37.91B |
| Novartis AG | 220.39B |
| MorphoSys AG | 2.632B |
| Illumina Inc | 18.12B |
| Pfizer Inc | 216.74B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 169.55M |
| Revenue (Quarterly) | 880.89M |
| Total Expenses (Quarterly) | 789.54M |
| EPS Diluted (Quarterly) | 0.75 |
| Gross Profit Margin (Quarterly) | 93.08% |
| Profit Margin (Quarterly) | 19.25% |
| Earnings Yield | 6.22% |
| Operating Earnings Yield | 5.92% |
| Normalized Earnings Yield | 5.463 |